Pharma Group Seeks Deadline Extension for GMP Compliance

In a significant development for the Indian pharmaceutical industry, the Indian Drug Manufacturers’ Association (IDMA) has formally requested an extension of the compliance deadline for good manufacturing practices (GMP) from the country’s health authorities. This plea comes as many production units, having submitted upgradation plans, demonstrate progress but face challenges in meeting the current deadline of December 31, 2023.

The IDMA has addressed a letter to the Health Secretary, emphasizing the need for an extension for existing applicants who can show measurable progress in their upgradation efforts. The association points out that numerous manufacturers, despite their good intentions and proactive steps toward compliance, may not complete all required activities within the designated timeframe.

Challenges such as the sequencing of civil and HVAC works, procurement lead times, validation schedules, and the availability of qualified technical resources are hindering timely completion, according to the IDMA. They are advocating for a case-by-case review mechanism, enabling manufacturers to continue on their compliance journey based on their individual project plans and progress.

The revised Schedule M of the Drugs and Cosmetics Rules, 1945, which outlines stringent quality norms for pharmaceutical manufacturing, was introduced in January 2022. Under these regulations, units with an annual turnover exceeding ₹250 crore were required to comply by July 1, 2023, while smaller manufacturers, classified as MSMEs, had a compliance deadline of January 1, 2024. Following requests for additional time, the ministry extended this deadline for MSMEs to December 31, 2023.

Despite this extension, many MSME manufacturers remain hesitant to apply for further extensions, citing unclear provisions within the revised Schedule M. The IDMA believes that offering additional conditional opportunities for compliance—extending the deadline to December 2026—would encourage these manufacturers to come forward with structured plans. This would allow them to confidently join the compliance pathway without the fear of regulatory repercussions.

As the deadline approaches, the IDMA’s advocacy highlights the balancing act between ensuring compliance with rigorous manufacturing standards and supporting the operational realities faced by many in the pharmaceutical sector. The association’s proactive stance reflects both a commitment to quality and a recognition of the complexities involved in upgrading manufacturing processes.

In summary, the request for an extension is a critical step in ensuring that Indian pharmaceutical manufacturers can meet evolving regulatory standards while continuing to deliver quality products. The IDMA’s engagement with the health authorities underscores the importance of collaboration in navigating the transition to enhanced GMP compliance.